RATIONALE: Omalizumab is a humanized IgG1k anti-IgE monoclonal antibody approved for treatment of chronic spontaneous urticaria (CSU). Details are lacking regarding the timing of omalizumab's clinical effect relative to high affinity IgE receptor (FcεRI) downregulation and its function on various cell types. The purpose of this study is to examine the kinetics of clinical symptom improvement relative to basophil phenotype shifts during treatment of CSU with omalizumab. METHODS: Adults with antihistamine-refractory CSU were recruited and treated with omalizumab 300 mg monthly for 90 days, following a 2 week run-in period to establish baseline symptoms. Subjects recorded Urticaria Activity Scores (UAS) twice daily, and weekly UAS-7 scores were calculated. Clinical assessments and blood sampling occurred at baseline and days 1, 3, 6, 10, 20, 30, 60 and 90 following initial omalizumab administration. Basophil measures included manual counts, blood histamine content, histamine release response, BAT and flow cytometric analysis of surface markers (IgE, FcεRI, CRTh2). RESULTS: A 50% reduction in UAS-7 scores was achieved on average by day 13 6 6 (n56) after the first dose of omalizumab. At that time, basophil counts following enrichment on Percoll increased by an average of 50%. Basophil surface IgE and FcεRI were reduced by 50% by day 6. Additionally, at the time of 50% symptom reduction, CRTh2 increased by approximately 30%. CONCLUSIONS: At the time of 50% symptom reduction in baseline UAS-7 scores with omalizumab therapy, basophil surface IgE and FcεRI were reduced. Increased CRTh2 expression and blood basophils were noted at the time of CSU symptom reduction. Icahn School of Medicine at Mount Sinai, New York, NY. RATIONALE: Current guidelines recommend against autoimmune testing for chronic urticaria (CU) without findings suggestive of autoimmunity. Despite the majority of cases being idiopathic, patients and referring physicians often consult A/I specialists to identify the etiology of disease. Here we describe current autoimmune laboratory testing practices and utility. METHODS: Retrospective chart review of patients evaluated at an allergy/immunology practice for CU. Autoimmune lab tests, biopsies, and resultant referrals were reviewed. RESULTS: Among 149 patients, autoimmune testing was performed in 81.2% (121) with 43.8% (53) being indicated based upon current autoimmune diagnosis (50.9%), family history of autoimmune disease (41.5%), concerning review of systems (37.7%), or abnormal rash quality (11.3%). The most common tests ordered included TSH (86.0%), C4 (47.9%), TPO (36.4%), and ANA (31.4%). The most frequently abnormal tests were ANA (31.58% 13/38), ESR (20.83% 5/24), SSA (16.7% 1/6), and thyroglobulin (14.0% 6/43). There was no difference between indication for testing versus whether testing was sent overall (OR 0.90, 95%CI 0.39-2.1) or for each individual test. Of the thirty-seven patients with abnormal results-45.9% resulted in no action, 54.1% were referred for further evaluation. Though those with testing indications, when compared to those without indication, did not have more abnormal results, they had 5 times greater odds of undergoing further intervention (OR 5.38,95% I 2.4-12.2). CONCLUSIONS: There was no association between testing indication and the ordering of tests or abnormal results. Routine extensive testing may lead to higher health care related costs without increased clinical benefit.
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